Worth Watching Stock’s News Analysis Report:Kansas City Southern (NYSE:KSU), Amgen, Inc. (NASDAQ:AMGN)

On Wednesday, Shares of Kansas City Southern (NYSE:KSU), subtract -10.88% and closed at $82.48 in the last trading session. The last trading range of the stock ranges between $79.30 and $83.71. The company’s Market capitalization is $8.97 Billion with the total Outstanding Shares of 107.58 million. Kansas City Southern (KCS) (KSU) declared recently that its 16th annual Holiday Express will distribute a total of $153,290 in gift cards to The Salvation Army at stops along the Holiday Express route. The gift cards are designated for the purchase of warm clothing and other necessities for kids in need.

“On behalf of the employees of Kansas City Southern, we look forward to bringing Santa Claus and his elves on the Holiday Express train to communities throughout our U.S. service territory, and we are especially happy to continue the tradition of charitable giving in each community where the train will stop,” said KCS president and chief executive officer Patrick J. Ottensmeyer.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $62.20 and reached to max level of $100.69. The EPS of company is strolling at 4.51.

Shares of Amgen, Inc. (NASDAQ:AMGN), jumped 5.76% and closed at $146.42 in the last trading session. The last trading range of the stock ranges between $142.75 and $152.85. The company’s Market capitalization is $108.33 Billion with the total Outstanding Shares of 743.92 million. Amgen (AMGN) recently declared that it will present data from multiple studies related to Enbrel® (etanercept), Prolia® (denosumab) and AMJEVITA™ (adalimumab-atto), in addition to investigational candidates, counting ABP 710 (infliximab biosimilar candidate) and romosozumab, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Washington, D.C., Nov.11-16, 2016.

In addition to highlighting key data from its clinical programs, Amgen studies will provide real-world insights on the patient journey and related unmet needs of those living with serious rheumatologic and bone diseases. Presentations also include long-term data assessing the clinical and economic impact of these diseases on patients and the overall healthcare system.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $133.64 and reached to max level of $176.85. The EPS of company is strolling at 10.01.

Leave a Reply

Your email address will not be published. Required fields are marked *